PRPH ProPhase Labs Inc

ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025

ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025

GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial results, and a review of current Company strategy, on a virtual conference call hosted by Renmark Financial on March 31, 2025 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on the company’s investor website.

REGISTER HERE:

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About ProPhase Labs

ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value.

Media Relations and Institutional Investor Contact:

ProPhase Labs, Inc.

Retail Investor Relations Contact:

Renmark Financial Communications

John Boidman

212-812-7680



EN
27/03/2025

Underlying

PRPHProPhase Labs Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProPhase Labs Inc

 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Engages RedChip Companies to Lead Investor Relations Eff...

ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it has engaged RedChip Companies (“RedChip”) to lead its investor relations efforts. “We are entering a transformative phase for ProPhase,” said Ted Karkus, CEO and Chairman of ProPhase Labs. “With the imminent commercialization of our BE-Smart™ esophageal cancer diagnostic, continued expansion of our Nebula Genom...

8h / 17m 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs to Present at the 2025 ThinkEquity Conference

ProPhase Labs to Present at the 2025 ThinkEquity Conference UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it will be participating in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. Ted Karkus, CEO and Chairman of ...

October 24, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Te...

ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology Study Acceptance Supports and Provides the Catalyst for Upcoming Commercial Rollout and Revenue-Generating Potential UNIONDALE, NY, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced today that its pivotal clinical study by Hartley et al. (2025) validating the BE-Smart™ esophageal cancer test has been accepted for publication in C...

October 22, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CR...

PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE COVID-19 TESTING LABORATORY SUBSIDIARIES FILE FOR BANKRUPCTY PROTECTION UNIONDALE, NY, Sept. 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced that its three COVID-19 testing laboratory companies filed for reorganization under Chapter 11 in United States Bankruptcy Court for the District of New Jersey, advancing the Crown Medical Collections initiat...

September 23, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 ...

ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor ProPhase Labs Stockholders Deliver Strong Mandate at Special Meeting UNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, today announced that stockholders delivered a strong mandate at the Company’s September 9, 2025 Special Meeting, approving all proposals on the agenda. With each proposal receiving more than 75% support, ProPhase received clear au...

September 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch